While the unprecedented challenges presented throughout 2020 have undoubtedly changed us all, we would like to take a moment to recognize the outstanding feats our team still managed to accomplish.

2020 Milestone Year in Review
1st Quarter

Several Thousand N95 Masks Donated
In response to the COVID-19
pandemic, Frontida has donated
several thousand units of personal
protection equipment, such as N95
masks and face shields, to local
Philadelphia healthcare providers,
Temple University Hospital and
Saint Joseph's Hospital
2nd Quarter

First IND Filing for FBHRS001
FB-HRS, LLC a joint venture, co-founded by Frontida BioPharm, Inc.
and Heart Rhythm Solutions, Inc.,
announced that the US FDA has
cleared an Investigational New
Drug (IND) application to initiate its
Clinical Trial of FBHRS001, a fixed
dose combination (FDC) of two
drugs, for the treatment of atrial
fibrillation.
3rd Quarter

Highly Potent Manufacturing Suite
Frontida's highly potent
compound facility expansion
features readily available,
hazard-certified production space
with the additional inclusion of a
large scale Roller Compactor,
Milling Room, Bin Blender,
Tablet Press, and ingress and
egress airlocks with enhanced
personnel controls. It is also now
available for 2021 quotes.
4th Quarter

Minority-Owned Business Certification
Frontida was granted full certifiable
recognition by The Eastern Minority
Supplier Development Council, a
501(c)(3) non-profit organization, as
a Minority-Owned Business
Enterprise. The EMSDC is the only organization capable of providing
this specific validation and
certification for Pennsylvania,
Southern New Jersey, and Delaware
businesses throughout the U.S.
2021

Coming Soon: Expansion of Services
Frontida has acquired ownership of AP-accredited and SAMHSA- and CLIAcertified toxicology laboratory research
and development department (Cat.One)
in the ongoing abuse-deterrent
formulation development of CNS
products with Drug Scan. These experts
have conducted more than 65 Category
One in vitro abuse-deterrent studies for
both brand and generic ADF developers,
and supported the manufacturing of four
brand named opioid products.
Come what may, these noteworthy achievements from 2020 have left us with high hopes for the future.
However, this remarkable growth phase would have not be possible without your continued support.
So from all of us at Frontida BioPharm, thank you and Happy New Year!
So from all of us at Frontida BioPharm, thank you and Happy New Year!